Multiple factors impact the treatment of acute bacterial skin and skin structure infections (ABSSSI). BAXDELA is your path forward.
aBAXDELA clinical trials included a distribution of patients with obesity, hypertension, diabetes, and renal impairment (eGFR > 15 mL/min/1.73 m2).
Oral monotherapySee BAXDELA Dosing & Administration
Melinta Therapeutics, Inc. - The Antibiotics Company
For medical inquiries or to report an adverse event, other safety-related information, or product complaints for a company product, please contact Medical Information. Phone: 1-844-MED-MLNT (1-844-633-6568)